Please sign in to follow a disease.
Which protein is safer for liver patients? new study compares whey and egg
NCT ID NCT07299110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how two different proteins—whey and egg white—affect blood ammonia levels in people with advanced liver disease caused by alcohol. High ammonia can harm brain function. Fifty patients will try both proteins on separate days, and their blood and thinking skills will be checked. The goal is to find out which protein is safer and guide better nutrition for liver patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Known or newly diagnosed (clinical, imaging) case of decompensated ethanol related cirrhosis patients. 2. Age (18-70 years). 3. Informed consent to participate in the study. Exclusion Criteria: 1. History of overt HE (West Haven grade II or more). 2. Last Intake \<1.5 months. 3. CKD (creatinine \>1.5 mg/dL), active infection, GI bleeding in past 2 weeks. 4. Severe anaemia (Hb \<7 g/dL) or hypoalbuminemia (\<2.0 g/dL). 5. Known egg or dairy allergy. 6. Those on sedatives, antidepressant or anti-psychiatric medication. 7. Unable to understand the language or instructions. 8. Hepatocellular Carcinoma. 9. TIPS. 10. Receiving rifaximin or lactulose. 11. Diarrhea, SIBO or malabsorptive syndrome.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis ethanol related are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institiute of liver and biliary sciences
RECRUITINGNew Delhi, 110070, India